REGN vs. NVO
REGN (Regeneron Pharmaceuticals, Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — REGN in Biotechnology, NVO in Drug Manufacturers - General. Over the past 10 years, REGN returned 6.24%/yr vs 8.20%/yr for NVO. Their 0.20 correlation means their historical movements had little consistent relationship.
Performance
REGN vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, REGN achieves a -0.16% return, which is significantly higher than NVO's -9.42% return. Over the past 10 years, REGN has underperformed NVO with an annualized return of 6.24%, while NVO has yielded a comparatively higher 8.20% annualized return.
REGN
- 1D
- 1.04%
- 1M
- 18.28%
- 6M
- -0.57%
- YTD
- -0.16%
- 1Y
- 35.60%
- 3Y*
- 0.37%
- 5Y*
- 4.87%
- 10Y*
- 6.24%
- ALL TIME*
- 10.60%
NVO
- 1D
- 0.56%
- 1M
- -9.60%
- 6M
- -2.34%
- YTD
- -9.42%
- 1Y
- -1.30%
- 3Y*
- -14.99%
- 5Y*
- -0.10%
- 10Y*
- 8.20%
- ALL TIME*
- 14.22%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $765.50M | $569.62M | $582.19M | |
| $660.53M | $541.93M | $661.12M |
REGN vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | -0.16% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | 2.42% |
NVO Novo Nordisk A/S | -9.42% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Correlation
The correlation between REGN and NVO is 0.26, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.26 |
Correlation (3Y) Balances recent behavior with more history. | 0.32 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.32 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.33 |
Correlation (All Time) Calculated using the full available price history since Apr 2, 1991 | 0.20 |
The correlation between REGN and NVO shifts across timeframes, from 0.20 (all time) to 0.33 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
REGN:
$79.18B
NVO:
$197.66B
REGN:
$40.34
NVO:
DKK 27.42
REGN:
19.05
NVO:
10.53
REGN:
5.31
NVO:
3.92
REGN:
2.11
NVO:
6.33
REGN:
$15.53B
NVO:
DKK 327.80B
REGN:
$13.69B
NVO:
DKK 268.30B
REGN:
$5.38B
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
REGN vs. NVO — Risk / Return Rank
REGN
NVO
REGN vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REGN | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.09 | ||
| Sortino ratioReturn per unit of downside risk | +1.38 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 1.04 | +0.17 |
| Calmar ratioReturn relative to maximum drawdown | 1.38 | -0.03 | +1.41 |
| Martin ratioReturn relative to average drawdown | 3.27 | -0.05 | +3.32 |
Loading charts...
Drawdowns
REGN vs. NVO - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for REGN and NVO.
Loading charts...
Drawdown Indicators
| REGN | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.81% | -74.70% | -17.11% |
Max Drawdown (1Y)Largest decline over 1 year | -25.85% | -43.67% | +17.82% |
Max Drawdown (3Y)Largest decline over 3 years | -59.69% | -74.70% | +15.01% |
Max Drawdown (5Y)Largest decline over 5 years | -59.69% | -74.70% | +15.01% |
Max Drawdown (10Y)Largest decline over 10 years | -59.69% | -74.70% | +15.01% |
Current DrawdownCurrent decline from peak | -35.52% | -67.64% | +32.12% |
Average DrawdownAverage peak-to-trough decline | -42.46% | -17.94% | -24.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.92% | 24.14% | -13.22% |
Volatility
REGN vs. NVO - Volatility Comparison
The current volatility for Regeneron Pharmaceuticals, Inc. (REGN) is 9.51%, while Novo Nordisk A/S (NVO) has a volatility of 12.94%. This indicates that REGN experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| REGN | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.51% | 12.94% | -3.43% |
Volatility (6M)Calculated over the trailing 6-month period | 23.33% | 33.87% | -10.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.65% | 46.70% | -13.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 31.06% | 38.73% | -7.67% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.16% | 32.67% | -0.51% |
Dividends
REGN vs. NVO - Dividend Comparison
REGN's dividend yield for the trailing twelve months is around 0.47%, less than NVO's 4.05% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 4.05% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
REGN Regeneron Pharmaceuticals, Inc. | 0.47% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
REGN vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REGN vs. NVO - Profitability Comparison
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 4.22B and revenue of 4.29B. Therefore, the gross margin over that period was 98.3%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 1.29B and revenue of 4.29B, resulting in an operating margin of 30.2%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 1.30B and revenue of 4.29B, resulting in a net margin of 30.2%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
REGN and NVO have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVO has higher volatility (12.94%) compared to REGN (9.51%). In terms of maximum drawdown, REGN dropped -91.81% vs NVO's -74.70%.
REGN currently has the higher Sharpe Ratio (1.06 vs -0.03), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for REGN and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer